<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13319">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933528</url>
  </required_header>
  <id_info>
    <org_study_id>DSXS 1538a</org_study_id>
    <nct_id>NCT02933528</nct_id>
  </id_info>
  <brief_title>Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS</brief_title>
  <official_title>An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS in Patients With Moderate to Severe Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following
      Maximal Use Treatment with DSXS .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the potential of DSXS topical product to suppress HPA axis function in patients
      with moderate to severe scalp psoriasis. Evaluate the efficacy parameters and adverse event
      (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp
      psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in the study with HPA axis suppression</measure>
    <time_frame>28 days</time_frame>
    <description>Hypothalamic Pituitary Adrenal (HPA) Axis Response to stimulation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Dsxs topical product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with DSXS once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSXS Topical product</intervention_name>
    <description>once daily for 28 days</description>
    <arm_group_label>Dsxs topical product</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating females 18 years of age or older.

          -  IRE-approved, signed informed consent form that meets all criteria of current FDA
             regulations.

        Exclusion Criteria:

          -  Females who are pregnant, nursing, planning to become pregnant during the duration of
             the study, or if of child-bearing potential and sexually active and not prepared to
             use appropriate contraceptive methods to avoid pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Yantovskiy</last_name>
    <phone>914-345-9001</phone>
    <email>natalie.yantovskiy@taro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taro Pharmaceuticals USA, Inc.</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Yantovskiy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>October 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
